Staff Pick /Features

ISAL 2017: Developments in acute leukemias

The International Symposium on Acute Leukemias (ISAL) 2017 was, as always, filled with data, scientific developments and debate. To capture…

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia

2 years

The bone marrow mesenchymal stem cell: exploring its role in MGUS and multiple myeloma

Multiple myeloma (MM) is an incurable malignant disease of plasma cells, representing the most severe form of paraproteinaemia. In most…

Multiple Myeloma

2 years

TIDEL II trial: uncovering the predictive value of ABCB1 in determining the long-term response to imatinib in CML patients

Adelaide researchers based at the South Australian Health and Medical Research Institute (SAHMRI) have demonstrated the significance of early increases…

Chronic Myeloid Leukemia

2 years

ASCO/EHA 2016: Combination therapies change the standard of care in multiple myeloma

As usual, the ASCO Annual Meeting and the EHA Annual Congress were a hub of activity, data and discussion. We…

Multiple Myeloma Promoted Post

2 years

Positive Phase III results for plitidepsin

Plitidepsin (also known as dehydrodidemnin B) is a first-in-class drug originally obtained from the sea squirt Aplidium albicans.[1] Plitidepsin specifically…

Multiple Myeloma

3 years

Staff Pick /Features

ISAL 2017: Developments in acute leukemias

The bone marrow mesenchymal stem cell: exploring its role in MGUS and multiple myeloma

TIDEL II trial: uncovering the predictive value of ABCB1 in determining the long-term response to imatinib in CML patients

ASCO/EHA 2016: Combination therapies change the standard of care in multiple myeloma

Positive Phase III results for plitidepsin

Subscribe